An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

This study will investigate the efficacy, safety and tolerability of a new formulation of glatiramer acetate administered at 20 mg/0.5 ml daily versus placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS).

Approximately 1400 participants were planned for this study, however only 178 were enrolled prior to early termination.

Eligibility Criteria:
Inclusion Criteria:

Subjects must meet all inclusion criteria in order to be eligible for the study:

* Subjects must have a confirmed and documented multiple sclerosis (MS) diagnosis as defined by the 2010 Revised McDonald criteria \[Ann Neurol 2011: 69:292-302\], with a relapsing-remitting disease course.
* Subjects must be ambulatory with a Kurtzke's Expanded Disability Status Scale (EDSS) score of 0-5.5 in both screening and baseline visits.
* Subjects must be in a relapse-free, stable neurological condition and free of corticosteroid treatment \[intravenous (IV), intramuscular (IM) and/or by mouth (PO)\] or ACTH (adrenocorticotropic hormone) 30 days prior to screening (Month-1) and between screening and baseline (Month 0) visits.
* Subjects must have experienced one of the following:
* At least one documented relapse in the 12 months prior to screening,
* At least two documented relapses in the 24 months prior to screening,
* One documented relapse between 12 and 24 months prior to screening with at least one documented T1-Gd enhancing lesion in a magnetic resonance imaging (MRI) performed within 12 months prior to screening.
* Subjects must be between 18 and 55 years of age, inclusive.
* Women of child-bearing potential must practice an acceptable method of birth control \[acceptable methods of birth control in this study include: surgical sterilization, intrauterine devices, oral contraceptive, contraceptive patch, long-acting injectable contraceptive, partner's vasectomy or a double-barrier method (condom or diaphragm with spermicide)\].
* Subjects must be able to sign and date a written informed consent prior to entering the study.
* Subjects must be willing and able to comply with the protocol requirements for the duration of the study.

Exclusion Criteria:

Any of the following conditions will exclude the subject from entering the study:

* Subjects with progressive forms of MS.
* Use of experimental or investigational drugs, and/or participation in drug clinical studies within the 6 months prior to screening.
* Use of immunosuppressive agents (including Mitoxantrone and Fingolimod) or cytotoxic agents within 6 months prior to the screening visit.
* Use of natalizumab (Tysabri®) or any other monoclonal antibodies within 2 years prior to screening.
* Use of cladribine within 2 years prior to screening.
* Previous treatment with immunomodulators \[including IFNβ 1a and 1b, and IV Immunoglobulin (IVIg)\] within 2 months prior to screening.
* Previous use of glatiramer acetate (GA) or any other glatiramoid.
* Chronic (more than 30 consecutive days) systemic (IV, PO or IM) corticosteroid treatment within 6 months prior to screening visit.
* Previous total body irradiation or total lymphoid irradiation.
* Previous stem-cell treatment, autologous bone marrow transplantation or allogenic bone marrow transplantation.
* Pregnancy or breastfeeding.
* Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation, as determined by medical history, physical exams, ECG, abnormal laboratory tests and chest X-ray. Such conditions may include hepatic, renal or metabolic diseases, systemic disease, acute infection, current malignancy or recent history (5 years) of malignancy, major psychiatric disorder, history of drug and/or alcohol abuse and allergies that could be detrimental according to the investigator's judgment.
* A known history of sensitivity to Gadolinium.
* Glomerular filtration rate (GFR) ≤ 60 mL/minute at the screening visit
* Inability to successfully undergo MRI scanning.
* A known drug hypersensitivity to Mannitol.
* Subjects who underwent endovascular treatment for chronic cerebrospinal venous insufficiency (CCSVI).